Autotelic Bio Receives the IND Approval for Phase 1 study from the MFDS for ‘Hypertension+Diabetes New Drug’. Autotelic Bio announced that the Ministry of Food and Safety (MFDS) of Korea has approved its IND (Investigational New Drug) for Phase 1 clinical study of ATB-101, which is a new drug candidate for chronic diseases, such as Hypertension and Diabetes, developed by Autotelic Bio, on 2nd. March, 2021. In addition, Autotelic Bio announced that they singed the co-development agreement with Korean pharmaceutical company called Firson.

Autotelic Bio Receives the IND Approval for Phase 1b study from the MFDS for Immuno-Target Oncology Product. Autotelic Bio announced that the Ministry of Food and Safety (MFDS) of Korea has approved its IND (Investigational New Drug) application for Phase 1b clinical study of ATB-301 on 17th. Feb. 2021. In addition, Autotelic Bio announced that the anti-cancer composition patent of ATB-301 has been granted.

Autotelic Bio announced that it has signed an agreement with a global pharmaceutical company, Clinigen Group in United Kingdom for clinical trials of ‘ATB-301’, Immuno-Target Dual Action Onco-therapeutic. Through this agreement, Clinigen group will supply Proleukin®, the global brand name for IL-2, to Autotelic Bio for various clinical trials.

NGenebio(CEO Daechul Choi), a company specializing in precision diagnosis platforms, signed a memorandum of understanding(MOU) with Autotelic Bio(CEO, Tae-hoon Kim), an innovative new drug research and development company, to develop NGS-based comorbid diagnosis technology. Through this MOU, both companies plan to develop a biomarker and genome NGS diagnosic panel for the comorbid diagnosis of ATB-301 and plan to apply it to screening target patients for clinical trials.

Autotelic Bio and Azoth Bio have entered to a co-development agreement of immnuo-oncology drug on September 7, 2020. This is a follow-up agreement, in about five months after the co-development agreement between them for targeted anti-cancer drugs in April, 2020.

Autotelic Bio announced that they had appointed two experts; MD. Yong-Kwan Jun, former director of Development Headquarters at Boryung Biopharma, and Ph. D. Chang-Hee Park, former project leader of NCE Discovery Team at Hanmi Pharm. Co., Ltd Research Center in August, 2020. Through this appointment, Autotelic Bio will focus its capabilities on clinical trials of new anti-cancer drugs; immuno-target dual action onco-therapeutic, development of additional anti-cancer pipelines and establishment of Anti-Sense Oligonucleotide(ASO) based technology.

Azoth Bio and Autotelic Bio have signed a co-development agreement for first in class targeted anti-cancer drugs. Both companies will develop the new anti-cancer drugs targeting proteins which are highly expressed in cancer cells. Azoth Bio will support development and optimization of the new drugs by its own AI platform and Autotelic Bio will preside development and efficacy test of the new drugs.

"Providing cancer patients with innovative new drugs improving significantly quality of life" Autotelic Bio is working on the development of new drug with significantly improved efficacy and side effects of existing anticancer drugs and with a sense of mission to provide innovative drugs to cancer patients around the world thus, improving the quality of life for cancer patients.

AutotelicBio & Jeil Pharm signed a joint development and technology transfer agreement for ATB-101 (Hypertension/Diabetes Incrementally modified drug)...

Autotelic Bio, a bio startup, located in Chungcheongbuk-do has R & D funding of 500 million matching achievements by selecting a TIPS task